Delivery Order SPE2DB25D3108-SPE2DB25FPDND
- Not listed
- The Defense Logistics Agency awarded a $2,205.54 delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injectors on August 13, 2025, with completion targeted for August 14, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injection, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.08 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 22, 2025, with completion targeted for August 25, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, addressing pharmaceutical...
- The Defense Logistics Agency awarded a $1,937.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies. This competitively awarded, non-set-aside contract was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, supporting the military...
- The Defense Logistics Agency awarded a delivery order valued at $1,721.26 to AmerisourceBergen Drug Corp for 0.5 mL of Xyosted 100 mg/0.5 mL auto-injector on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy...
- The Defense Logistics Agency awarded a delivery order valued at $3,816.88 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector supplies. This non-set-aside, firm fixed-price delivery order was executed on August 12, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product used in the treatment of hormone deficiency, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with a ceiling value of $1,314.73 under a firm fixed-price arrangement. The contract was competitively awarded without set-aside provisions and is due for completion by September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- The Defense Logistics Agency awarded a delivery order valued at $2,393.02 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy medication delivered via auto-injector,...
- The Defense Logistics Agency awarded a delivery order valued at $3,706.98 to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector supplies on September 10, 2025, with completion targeted for September 11, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product delivered via...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDNDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,755.76 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies. This non-set-aside, firm fixed-price delivery order was executed on August 1, 2025, with an ultimate completion date of August 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product used in military and federal healthcare settings to support servicemembers and beneficiaries requiring endocrine treatment. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, supplying medications, vaccines, and medical devices across multiple therapeutic categories to military healthcare systems and other federal agencies. The competitively awarded IDC demonstrates the contractor's capability to meet federal pharmaceutical supply requirements and enables flexible fulfillment of diverse medical commodity needs across global military operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/1/25 |